Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.

When we compared the TNFi versus CS monotherapy groups among patients with any tumor type, we found a nearly significant higher risk of all-cause mortality (HR 2.88, 95% CI 1.00-8.35, p=0.05) ( Figure 4A ) and a trend toward a significant higher risk of progression (HR 1.96, 95% CI: 0.94-4.08, p=0.07) ( Figure 4C ).

also in 3,349 other papers